APA (7th ed.) Citation

Platzbecker, U., Krämer, A., & Bochtler, T. (2018). Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): An open-label, multicentre, phase 2 trial. The lancet. Oncology, 19(12), . https://doi.org/10.1016/S1470-2045(18)30580-1

Chicago Style (17th ed.) Citation

Platzbecker, Uwe, Alwin Krämer, and Tilmann Bochtler. "Measurable Residual Disease-guided Treatment with Azacitidine to Prevent Haematological Relapse in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukaemia (RELAZA2): An Open-label, Multicentre, Phase 2 Trial." The Lancet. Oncology 19, no. 12 (2018). https://doi.org/10.1016/S1470-2045(18)30580-1.

MLA (9th ed.) Citation

Platzbecker, Uwe, et al. "Measurable Residual Disease-guided Treatment with Azacitidine to Prevent Haematological Relapse in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukaemia (RELAZA2): An Open-label, Multicentre, Phase 2 Trial." The Lancet. Oncology, vol. 19, no. 12, 2018, https://doi.org/10.1016/S1470-2045(18)30580-1.